Caspofungin + Amphotericin B Deoxycholate

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidiasis, Invasive

Conditions

Candidiasis, Invasive

Trial Timeline

Jan 15, 2014 → Feb 28, 2018

About Caspofungin + Amphotericin B Deoxycholate

Caspofungin + Amphotericin B Deoxycholate is a phase 2 stage product being developed by Merck for Candidiasis, Invasive. The current trial status is terminated. This product is registered under clinical trial identifier NCT01945281. Target conditions include Candidiasis, Invasive.

What happened to similar drugs?

5 of 20 similar drugs in Candidiasis, Invasive were approved

Approved (5) Terminated (4) Active (12)

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01945281Phase 2Terminated

Competing Products

20 competing products in Candidiasis, Invasive

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPhase 1
29
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Fluconazole + MicafunginAstellas PharmaApproved
35
Micafungin + CaspofunginAstellas PharmaPhase 3
40
Micafungin + FluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPhase 2
35
micafungin + caspofunginAstellas PharmaPhase 3
40
micafungin + amphotericin B deoxycholateAstellas PharmaPhase 3
32
FK463Astellas PharmaPhase 2
35
Micafungin + Liposomal Amphotericin BAstellas PharmaPhase 3
40
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
36
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
36
L-743,872MerckPre-clinical
26
CaspofunginMerckPhase 2
35
L-743,872MerckPhase 2
27
Caspofungin acetate + PlaceboMerckPhase 2
27
Caspofungin + Normal SalineMerckApproved
43
caspofungin acetateMerckPhase 3
40